The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of MBX Biosciences Inc (NASDAQ: MBX) closed at $14.91 in the last session, down -5.99% from day before closing price of $15.86. In other words, the price has decreased by -$5.99 from its previous closing price. On the day, 0.63 million shares were traded. MBX stock price reached its highest trading level at $15.915 during the session, while it also had its lowest trading level at $14.8.
Ratios:
We take a closer look at MBX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 19.50 and its Current Ratio is at 19.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On August 05, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $38.
On July 16, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $38.Oppenheimer initiated its Outperform rating on July 16, 2025, with a $38 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 26 ’25 when Heron Patrick J bought 666,666 shares for $18.00 per share. The transaction valued at 11,999,988 led to the insider holds 5,219,440 shares of the business.
Pescovitz Ora H. bought 7,693 shares of MBX for $45,312 on Apr 08 ’25. The Director now owns 24,329 shares after completing the transaction at $5.89 per share. On Feb 18 ’25, another insider, GORDON CARL L, who serves as the Director of the company, bought 143,170 shares for $10.84 each. As a result, the insider paid 1,551,963 and bolstered with 3,255,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MBX now has a Market Capitalization of 666708032 and an Enterprise Value of 276628544.
Stock Price History:
The Beta on a monthly basis for MBX is 1.09, which has changed by -0.366879 over the last 52 weeks, in comparison to a change of 0.118204355 over the same period for the S&P500. Over the past 52 weeks, MBX has reached a high of $27.50, while it has fallen to a 52-week low of $4.81. The 50-Day Moving Average of the stock is 6.87%, while the 200-Day Moving Average is calculated to be 25.71%.
Shares Statistics:
According to the various share statistics, MBX traded on average about 1.13M shares per day over the past 3-months and 970750 shares per day over the past 10 days. A total of 33.59M shares are outstanding, with a floating share count of 20.67M. Insiders hold about 53.79% of the company’s shares, while institutions hold 48.66% stake in the company. Shares short for MBX as of 1759190400 were 3900619 with a Short Ratio of 3.46, compared to 1756425600 on 3843321. Therefore, it implies a Short% of Shares Outstanding of 3900619 and a Short% of Float of 13.969999999999999.
Earnings Estimates
The market rating of MBX Biosciences Inc (MBX) is currently shaped by the ongoing analysis conducted by 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.57 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.37 and -$2.9 for the fiscal current year, implying an average EPS of -$2.65. EPS for the following year is -$2.54, with 5.0 analysts recommending between -$2.21 and -$2.78.
